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 Persistent chlamydial infections and the challenges for vaccine 
development 
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The development of chlamydial vaccines continues to be a major challenge 
for researchers. While acute infections are the main target of vaccine 
development groups, Chlamydia is well known for its ability to establish 
chronic or persistent infections in its host. To date, little effort has focussed 
specifically on the challenges of vaccines to successfully combat the chronic 
or persistent phase of the disease and yet this will be a necessary aspect of 
any fully successful chlamydial vaccine. This short review specifically 
examines the phenomenon of chlamydial persistence and the unique 
challenges that this brings to vaccine development. 
 
The phenomenon of chlamydial persistence 
 
Molecular evidence for chlamydial persistence was first reported by Beatty et 
al. back in 1994 and since then been supported by over 50 published reports 
on various aspects of the topic. The phenomenon of chlamydial persistence 
has best been described as “a viable but non-cultivable growth stage resulting 
in a long-term relationship with the infected host” (Hogan et al., 2004). Such 
relationships have been most thoroughly analysed in vitro, usually by 
perturbing the cell culture conditions in some way, such as; (a) amino acid 
deficiency (Coles et al., 1993), (b) specifically by limiting tryptophan, (c) iron 
depletion (Raulston et al., 1997), (d) exposure to interferon gamma (Pantoja 
et al., 2001), (e) antibiotic exposure (Kutlin et al., 1999), (f) phage infection 
(Hsia et al., 2000), (g) or a continuous infection model (Kutlin et al., 2001).  In 
all cases, the morphological hallmarks of persistence are; (a) a block in the 
chlamydial developmental cycle such that reticulate bodies (RBs) do not 
convert back to elementary bodies (EBs) and hence the cycle is not 
completed, (b) a large reduction in the infectious titre, which results directly 
from the lack of production of EBs, (c) enlarged and abnormally shaped RBs 
 inside enlarged inclusions, (d) in some cases, increased resistance to 
antibiotics. 
 
While persistence has been best characterised in vitro, there is also 
considerable in vivo evidence to support it. These include observations of 
altered morphological forms in vivo, detection of chlamydial DNA and antigen 
in diseased hosts but without the ability to recover culturable chlamydiae, as 
well as recurrences of infections in a single host that do not appear to be due 
to  reinfection. 
 
While it continues to be difficult to visualise persistent forms in the diseased 
host, there have been several reports of such altered forms in both humans 
and animals. Atypical, pleomorphic RBs with poorly defined outer membranes 
were observed by Nanagara et al. (1995) in infected fibroblasts and 
macrophages in synovial membrane samples from patients with 
C.trachomatis-associated reactive arthritis. More recently, abnormal 
C.pneumoniae forms have been observed within aortic valve samples from 
patients with degenerative aortic valve stenosis (Skowasch et al., 2003). 
 
Detection of chlamydial DNA and/or antigens in the absence of recoverable 
infectivity is not uncommon and has been reported in in a range of human 
disease states. Chlamydial DNA and antigen for instance can often be 
detected in tubal bioposy specimens, particularly following inadequate 
antibiotic treatment (Patton et al., 1994). Similarly, chlamydial RNA, which 
indicates viable Chlamydiae, has been detected in the absence of cultivability 
in experimental trachoma infections of primates (Holland et al., 1992) as well 
as in synovial biopsy samples from patients with reactive arthritis or Reiter’s 
syndrome (Gerard et al., 1998). 
 
The third area of proof of persistent forms in vivo comes from observations 
such as Dean et al. (2000) in a study of women with genital C.trachomatis 
infections who demonstrated recurrences of the same genotype of 
C.trachomatis in patients over a 2 to 4.5 year period. This strongly argues 
 against new infections, but rather suggests a long term chronic or persistent 
infection in these women. 
 
Probably the most significant evidence for persistence however has been the 
molecular analyses that have occurred in the past 4 – 5 years. A series of 
transcriptomic and more recently proteomic studies are clearly demonstrating 
that Chlamydia posess a persistence regulon that responds to harsh external  
conditions by altering the chlamydial transcriptional pathways used. By using 
various in vitro models, such as interferon gamma induction, iron depletion or  
penicillin treatment, several groups have shown altered RNA expression 
profiles (Hogan et al., 2003; Belland et al., 2003; Nicholson and Stephens 
2002; Mukhophaday et al., 2005; Timms et al., 2005). Hogan et al. (2003) first 
used the long term continuous model of persistence and more recently 
(Hogan et al., unpublished data) the interferon gamma induction model 
combined with quantitative RT-PCR analyses on C.pneumoniae to show 
significant up- and down-regulation of several key genes under persistence 
conditions. Nicholson and Stephens (2002) reported the first whole genome 
microarray data with C.trachomatis persistence using penicillin as the 
persistence inducing factor. Belland et al. (2003) subsequently performed a 
whole genome microarray experiment on C.trachomatis using the most widely 
accepted interferon gamma induction method. They also demonstrated that 
the persistence response was reversed when tryptophan was added back to 
the system. One aspect of chlamydial persistence has been the fact that while 
some gene responses seem to be consistently observed between models, 
others appear to vary. Timms et al. (unpublished data) recently studied this 
aspect by comparing the interferon gamma induction and iron limitation 
models of persistence with C.pneumoniae.  They drew some conclusions 
about the most consistent features of chlamydial persistence, at least at the 
transcriptomic level. They noted that of the genes that have been analysed in 
several previous studies, only four show consistent changes in all Chlamydia 
and across all persistence models; hctB, omcB, ompA and crpA are all down-
regulated while htrA is usually up-regulated. The down-regulation of hctB is 
probably predictable, being a late gene involved in DNA condensation, and it 
it appears to be one of the better late gene markers of persistence. The 
 consistent down-regulation of the cell wall/envelope genes, omcB, pmpA and 
crpA is interesting and could possibly suggest that Chlamydia has evolved a 
mechanism to dampen its immune induction by limiting the expression of its 
antigenic wall components. The interferon-gamma induction model has been 
the best studied persistence model by far, and in addition to the four model-
wide hallmarks mentioned above, five other genes appear to give consistent 
changes in both chlamydial species specifically in the interferon-gamma 
induction model; groES, dnaK, grpE and ndk are all down-regulated while tyrP 
is up-regulated. Timms et al. (2005) also noted that the down-regulation of 
several stress response genes is less obvious and either suggests that this 
component of the stress response is deleterious to parasite survival, or else 
that transcriptional control of these genes is not as important as translational 
control mechanisms. Comparison of persistence markers between the 
chlamydial species is less straightforward, as many studies have not 
compared the same genes. It seems obvious however that there are 
numerous examples of species differences in the transcriptional response to 
persistence and this might suggest important differences in the evolution of 
the two species in their response to host-induced persistence. 
 
Taken together however, the transcriptomic and more recently the proteomic 
studies on several persistence models demonstrate that this is not just a 
stress response by the Chlamydia, but is clearly a directed response by the 
parasite, presumably to ensure its longer term survival. 
 
Implications for vaccine development 
 
The development of effective chlamydial vaccines has been a major challenge 
for the past 20 years or more (reviewed by Igetsieme). This difficulty is partly 
due to the need to identify the most protective chlamydial antigens but also to 
the need to induce strong mucosal immunity. The currently held view is that a 
strong antibody response is able to neutralise the EBs when they are first 
encountered at the site of infection while a strong T cell response is required 
to detect and destroy infected cells once the infection has become 
established.  
  
Clinical persistence is a key concept in the pathogenesis of chlamydial 
infections. Sterility caused by genital infection with C.trachomatis and 
coronary artery disease associated with C.pneumoniae are both caused by 
inflammation-based pathology.  Chlamydial antigens may persist for 
prolonged periods and there is evidence that these non-cultivable forms may 
lead to continued inflammation.  Persistence of the microorganisms thus 
raises the question of optimal therapy as well as presenting a unique 
challenge to the development of effective vaccines. 
 
Immune responses that are associated with persistent infection with 
C.trachomatis seem to induce pathology as a result of chronic inflammation 
and tissue damage. The induction of a delayed-type hypersensitivity (DTH) 
reaction to C.trachomatis antigens  leads to repeated and persistent infection 
of the upper reproductive tract. Indeed there is a strong correlation between 
Chlamydia-specific immune responses, such as antibodies and T cells 
specific for heat -shock protein 60 (HSP60) from chlamydia spp., and PID and 
fallopian tube pathology (Brunham and Peeling 1994) It is known that T cells 
that are reactive to C.trachomatis HSP60 and produce IL-10 have been found 
in infertile women (Kinnunen et al., 2003) and thus may be involved in the 
suppression of C.trachomatis specific responses, which could contribute to 
the ability of C.trachomatis to persist. Heat shock protein 60 (HSP60) from 
Chlamydia pneumoniae also triggers cytokine responses including TNF and 
IL-12p40 inflammatory responses via Toll-like receptor 2 and 4 in vivo and it 
can be also found in atherosclerotic plaques of patients (DaCosta et al. 2004). 
 
Some clinical and animal studies have also shown that heat shock protein 10 
(HSP10) is another chlamydial antigen implicated in the immunopathogenesis 
of chlamydial infection. Chlamydial heat shock protein 10 was identified as a 
correlate to the immunopathogenic process in women with tubal factor 
infertility (LaVerda et al. 2000). Serum IgA antibodies to HSP60 and HSP10 
were significantly higher in the female partners of subfertile (time to 
pregnancy > or = 12 months) couples than in their fertile controls (Karinen, et 
al., 2004). Chlamydial HSP60 and HSP10 antigen-specific antibodies were 
 also associated with uterine and salpingeal fibrosis in Chlamydia-infected 
koalas. (Higgins et al., 2005)  
 
A recent study in the macaque model however reports that recombinant 
chlamydial heat shock protein 60 (rcHSP60)  was the only antigen shown to 
induce significant delayed-type hypersensitivity from a panel of many other 
chlamydial antigens tested that included UV-inactivated organisms 
recombinant major outer membrane protein (MOMP), purified outer 
membrane proteins (OMP)  and heat shock protein 10 (HSP10) 
(Lichtenwalner et al., 2004). However it was noted in this study that mild 
reactions to MOMP, OMP and HSP10 were also observed but the differences 
from controls were not statistically significant. It is possible that weak DTH 
reactions induced by testing with antigens other than rcHSP60 may not have 
been detected. 
 
In terms of designing an effective C.trachomatis vaccine that does not induce 
a delayed type hypersensitivity (DTH) reaction it would appear that it is 
imperative to omit antigens to chlamydial HSP60 from a vaccine for use 
against genital chlamydial infections in the naïve vaccinated host. If the 
population of women to be vaccinated have previously been exposed to 
Chlamydiae and already have tubal factor infertility (TFI) it would be prudent 
to also exclude antigens to C-reactive protein (CRP) and HSP10 from the 
vaccine (since among women with similar exposure to chlamydiae the 
serologic responses were recorded against chlamydial CRP (denHartog 2005 
and the responses to HSP10 showed a stronger correlation with TFI than did 
the responses to HSP60 or MOMP (LaVerda et al., 2000).  In vaccines 
designed to protect against C.pneumoniae infection that is associated with 
atherosclerosis (an emerging risk factor in coronary artery disease) 
chlamydial HSP60 and lipopolysaccharide should likely be omitted from the 
formulation since these chlamydial antigens have been shown to dysregulate 
lipid metabolism, induce inflammatory cytokine cascades and trigger 
production of cross-reactive antibodies that initiate and promote 
atherogenesis (Kalayoglu, 2002). 
 
 If persistent infections are established in susceptible hosts then those 
infections may serve as reservoirs for new infections, contribute to the 
immunopathological consequences of infection or require alternative 
therapeutic approaches.  An effective chlamydial vaccine must therefore 
target the persistent phase and not just initial phase of infection in these 
hosts. 
 
Sera of subfertile women with tubal pathology  test positive for the presence 
of IgG and IgA antibodies to C.trachomatis, IgG antibodies to cHSP60 and C-
reactive protein (CRP)  (denHartog et al., 2005) all serological markers of 
persistent C.trachomatis infections. Therefore antibodies are not likely to be 
effective against the persistent stage of chlamydial infection. This salient 
observation from the results of many clinical and animals studies on 
chlamydial genital tract infections is an important one to consider for vaccine 
development. . Effective vaccine design needs to consider not only the fact 
that (1) Th1 cells are essential for resolution of chlamydial genital tract 
infection but also that (2) the microorganism is capable of abnormal growth 
and persistence as part of its developmental cycle and therefore (3) two 
distinct populations of humans/animals will be involved in vaccine studies. 
The first population are naïve hosts in whom it will be imperative that the 
vaccine used stimulates a rapid and strong MHC classII-restricted, CD4+ T-
helper type 1 (Th1) response mediated by IFN-y and TNF-a production which  
is crucial for resolving primary infection (reviewed by Igietseme et al., 2004) 
and which should not result in the establishment of chronic infection. .An 
inadequate or sub-optimal Th1 response may lead to the establishment of 
persistent infection resulting in the second population that will need to be 
vaccinated . In this second population it will be crucial to design a vaccine that 
omits chlamydial antigens capable of stimulating DTH responses and that 
also targets the abnormal growth  and persistence phase of the organisms life 
cycle. 
 
Our own group has several potential chlamydial persistence antigens that can 
be tested in a vaccine that targets both the acute and the persistent stages of 
infection – both of which are the result of (1) infection of the host cell 
 cytoplasmic membrane and (2) abnormal growth and persistence of the 
organism- two of the known stages of the chlamydial developmental cycle 
(AbdelRahman,and Belland, 2005). It would appear that the most effective 
vaccine would be a multi-subunit one especially considering recent evidence 
reporting that a novel, multiple subunit vaccine induced a higher frequency of 
Th1 cells against Chlamydia trachomatis compared with a single subunit 
construct (Eko et al., 2004).  Thus it would appear that an effective chlamydial 
vaccine will need to have multiple sub-units some of which are directed 
against acute antigens and others directed against persistent antigens. 
 
Finally, it will also be imperative for any novel vaccine trials to evaluate what 
effect(s) immunising against persistence antigens will have in situations where 
chlamydial infections of animals/people are either inapparent (subclinical)  or 
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